• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • New NMPA Measures for Random Medical Device Checking In-market

New NMPA Measures for Random Medical Device Checking In-market

Friday, 20 March 2020 / Published in Medical Device

New NMPA Measures for Random Medical Device Checking In-market

On 13.03.2020, the NMPA announced (No.09-2020) the Administrative Measures for the Sampling Inspection on the Quality of Medical Devices. This is a new measure designed to increase NMPA’s post-market surveillance and applies to all registered medical devices sold in China.

According to the administrative measures, the NMPA focus is on conducting sampling inspections on medical devices in the market including, but not limited to, those medical devices with the following features:

1. with high safety risks and requiring special supervision;
2. involving a high dosage amount, a wide population of users, and a wide range of uses;
3. for which many complaints have been received and public concerns have been raised;
4. where adverse event reporting indicates possible quality issues; or
5. for which product quality is easily affected by the conditions of storage and transportation.

On the contrary, the provincial MPAs will focus their sampling inspection on medical devices including, but not limited to, those medical devices with the following features:

1. where the product has been registered or filed within the relevant provincial administrative area;
2. with relatively high safety risks and not otherwise included in the list of product categories for inspection;
3. listed in the previous year’s sampling inspection plan, but not yet inspected; or
4. for which daily monitoring and adverse event reporting indicates possible quality issues.

The NMPA legal agents are required to fully cooperate throughout the inspection process for imported medical devices. If there is any objection to the inspection results, the application for re-inspection must be submitted within 7 working days after the issued date of the inspection report.

Tagged under: Sampling Inspection

What you can read next

Clinical Trials & Import of Veterinary Drugs
Overseas Innovative Medical Device Fast-Track Approval
Second Overseas Innovative Medical Device in 2020 Approved via Green Channel
New CNAS Accreditation for Group Enterprise Internal Laboratories Explained

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP